Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Hematology
Reference26 articles.
1. Shaw JR, Siegal DM (2018) Pharmacological reversal of the direct oral anticoagulants-a comprehensive review of the literature. Res Pract Thromb Haemost 2(2):251–265. https://doi.org/10.1002/rth2.12089
2. Frontera J, Joset D, Lalchan R, Ahuja T, Papadopoulis J (2019) 875: Cost comparision of andexanate versus PCC for direct factor XA inhibitor reversal after hemorrhage. Critical Care Med 47:1
3. Heo Y-A (2018) Andexanet alfa: first global approval. Drugs 78(10):1049–1055. https://doi.org/10.1007/s40265-018-0940-4
4. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH et al (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380(14):1326–1335. https://doi.org/10.1056/NEJMoa1814051
5. Tomaselli Gordon F, Mahaffey Kenneth W, Cuker A, Dobesh Paul P, Doherty John U, Eikelboom John W et al (2020) 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol 76(5):594–622. https://doi.org/10.1016/j.jacc.2020.04.053
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献